A biotechnology pioneer company in developing a novel class of drugs based on Nanoparticle delivery to treat Cancer and Neurological Diseases.

Onselex Pharmaceuticals is a biotechnology company advancing a next-generation nanomedicine platform designed to improve the therapeutic index of established oncology drugs. Our focus is to expand efficacy while meaningfully reducing systemic toxicity through precise nanoparticle delivery.

Our lead program, ONX-1006, is a nanoparticle drug candidate engineered to securely encapsulate paclitaxel within a stable structure. The design is intended to enhance tumor accumulation while reducing off-target exposure to healthy cells. Across extensive GLP toxicology and preclinical studies, ONX-1006 has established No Observed Adverse Effect Level (NOAEL), compared to conventional paclitaxel formulations, supporting the potential for sustained administration and much improved treatment standards without Treatment emergent adverse events (TEAEs).

We are currently focused on metastatic pancreatic cancer, one of the most aggressive and underserved malignancies in oncology. Despite decades of therapeutic development, survival outcomes remain limited, particularly in late-stage disease. Current standard regimens such as FOLFIRINOX and Abraxane provide incremental benefit, yet significant unmet need persists. In validated xenograft models, ONX-1006 demonstrated statistically significant and superior tumor suppression compared to Abraxane. These findings, combined with a strong preclinical safety profile, support advancement toward clinical evaluation. Our long-term vision extends beyond a single indication. The underlying nanoparticle architecture has the potential to serve as a broader platform technology applicable across multiple solid tumors and, in the future, neurological indications.

At Onselex, we are committed to disciplined science, rigorous development, and responsible execution. Our mission is to advance therapies that enable patients to regain stability, independence, and quality of life.

We sincerely appreciate our partners and long term shareholders who share our vision and recognize the importance of disciplined clinical advancement in transformative oncology innovation.

If you would like to join Onselex as a shareholder and embark on this remarkable but challenging journey together, please email us. Thank you very much for your considerations.

Ernie Shin